Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) - Equities researchers at Wedbush issued their FY2029 earnings per share estimates for shares of Aerovate Therapeutics in a report released on Monday, February 24th. Wedbush analyst L. Chico forecasts that the company will earn ($0.74) per share for the year. The consensus estimate for Aerovate Therapeutics' current full-year earnings is ($2.64) per share.
Aerovate Therapeutics Price Performance
Shares of Aerovate Therapeutics stock traded up $0.01 during trading on Wednesday, reaching $2.43. 121,336 shares of the stock traded hands, compared to its average volume of 182,188. The company has a market capitalization of $70.17 million, a price-to-earnings ratio of -0.81 and a beta of 0.99. The business has a fifty day simple moving average of $2.54 and a two-hundred day simple moving average of $2.35. Aerovate Therapeutics has a 52-week low of $1.25 and a 52-week high of $32.42.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in the company. Jefferies Financial Group Inc. purchased a new position in shares of Aerovate Therapeutics during the fourth quarter valued at about $1,590,000. GTS Securities LLC purchased a new position in Aerovate Therapeutics in the fourth quarter worth about $27,000. Squarepoint Ops LLC purchased a new position in Aerovate Therapeutics in the fourth quarter worth about $52,000. Two Sigma Advisers LP grew its position in Aerovate Therapeutics by 38.5% in the fourth quarter. Two Sigma Advisers LP now owns 153,600 shares of the company's stock worth $407,000 after acquiring an additional 42,700 shares in the last quarter. Finally, Bridgeway Capital Management LLC purchased a new position in Aerovate Therapeutics in the fourth quarter worth about $159,000.
Aerovate Therapeutics Company Profile
(
Get Free Report)
Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.
Read More
Before you consider Aerovate Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aerovate Therapeutics wasn't on the list.
While Aerovate Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
